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Introduction
The aim of the meeting was to provide an overview of the
ways in which modulation of cytokines may be important in
the pathogenesis and treatment of systemic lupus erythe-
matosus (SLE). It comprised a set of 11 talks from an inter-
national group of speakers followed by a vigorous
discussion.
Marc Feldmann (Kennedy Institute of Rheumatology,
London, UK) and David Isenberg (University College
London, UK) welcomed the 50 participants, emphasizing
the diversity (clinical and serological) of SLE and the likely
complexity of cytokine involvement in its development.
Two major themes emerged from the meeting. First, lupus
is a complex disease and many different elements con-
tribute to its pathogenesis. These include factors that are
intrinsic to the immune system, such as B or T lymphocyte
dysfunction, and factors that are extrinsic to the immune
system but linked to it, such as abnormal clearance of
apoptotic cells or endothelial activation. All of these
factors represent potential targets for cytokine action and
hence manipulation, and many different cytokines may be
involved. Second, although many cytokines may be
involved in the pathogenesis of SLE, research thus far has
concentrated on a small group of cytokines, notably
tumour necrosis factor (TNF)-α and IL-10. Evidence relat-
ing to these cytokines was considered in detail in several
of the presentations.
Mechanisms in the pathogenesis of systemic
lupus erythematosus
Mark Walport (Imperial College London, UK) described
the evidence suggesting that delayed or deficient removal
of debris from dying cells may play a role in the develop-
ment of autoantibodies in SLE [1]. It has been shown that
phagocytes from patients with SLE and from lupus prone
mice have impaired ability to ingest such material in vitro.
Material from dying cells such as apoptotic blebs and
apoptotic bodies that are not efficiently removed because
of this impairment may reach lymphoid tissues and act as
antigenic stimuli. The surfaces of apoptotic bodies carry
complexes of molecules that are known autoantigens in
patients with SLE and related disorders, such as DNA,
histones, anionic phospholipids and β2-glycoprotein I [2].
Such antigens are not generally found on the surfaces of
intact nonapoptotic cells. Furthermore, the binding of
complement component C1q to these complexes may
explain the production of anti-C1q antibodies, which is
found in approximately one-third of patients with SLE [3].
Cytokines may be involved in this abnormal clearance of
cellular debris. For example, the physiological phagocyto-
sis of apoptotic material is associated with the release of
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Abstract
The meeting consisted of 11 talks that illustrated the complexity of the pathogenetic mechanisms
underlying systemic lupus erythematosus and aimed to identify ways in which cytokine modulation
might affect those mechanisms. The evidence relating to the involvement of tumour necrosis factor-α,
interleukin-10 and BLyS in this disease was discussed in particular detail. A final discussion explored
the possible ways in which cytokine modulation might lead to new methods of treating systemic lupus
erythematosus in the future.
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anti-inflammatory cytokines such as transforming growth
factor-β, whereas this is likely to be altered under condi-
tions of delayed phagocytosis in SLE.
Sir Ravinder Maini (Kennedy Institute of Rheumatology,
London, UK) pointed out that the production of anti-DNA
antibodies in some patients treated with anti-TNF-α drugs
could be related to this mechanism of impaired waste dis-
posal. Cells bearing surface TNF-α are lysed by the anti-
body in vitro, thus increasing the amount of cellular debris
to be removed. However, there is no evidence of this
mechanism in vivo, although nucleosome antigens result-
ing from apoptosis are detectable during the normal course
of disease in the joints and blood of rheumatoid patients.
These would provide the immunogenic drive for antinuclear
antibody production. In anti-TNF treated patients the nucle-
osomal load may be coupled with reduced removal of this
debris as a result of reduction in circulating levels of
C-reactive protein and serum amyloid protein A.
Michael Ehrenstein (University College London, UK)
emphasized the fact that many different mechanisms may
lead to the development of SLE. A large number of differ-
ent and unrelated murine models show clinical and/or his-
tological features akin to human SLE [4]. Although many
of these models are deficient in functions related to lym-
phocytes or clearance of apoptotic cells, there are others
in which there is no apparent rationale for the develop-
ment of a lupus-like disease. There is no consistent
cytokine pattern common to all of the models.
A number of these models are characterized by abnormal
B-cell function. For example, mice deficient in secreted (but
not membrane bound) IgM develop autoantibodies and
deposition of immunoglobulin and C3 in their kidneys [5].
These mice exhibit expansion of marginal zone B cells and
an increase in the number of B1 cells. The self-renewing
B1 compartment is also expanded in lupus-prone NZB/W
F1 mice, and these B1 cells can secrete autoantibodies.
Proliferation of B1a cells in NZB/W F1 mice is dependent
on IL-10 and stromal cell derived factor (SDF)1.
The cytokine BLyS, a member of the TNF family, is impor-
tant in the development of B lymphocytes. Jane Gross
(Zymogenetics Inc., Seattle, WA, USA) reviewed the evi-
dence that BLyS is important in the pathogenesis of SLE.
BLyS is elevated in the serum of patients with SLE, and
mice that constitutively over-express BLyS develop
autoantibodies and glomerulonephritis.
Dorian Haskard (Imperial College London, UK) outlined
ways in which the effects of cytokines on the vasculature
may contribute to the pathogenesis of SLE. Intravital
microscopy shows that transmigration of TNF-α-stimu-
lated leucocytes through chronically activated endothe-
lium is enhanced in lupus prone MRL lpr/lpr mice as
compared to wild-type MRL mice. Similar enhanced leuco-
cyte–endothelial cell interactions may also occur in
patients with SLE, in whom circulating levels of TNF-α are
sufficient to stimulate the expression of intercellular cell
adhesion molecule-1, vascular cell adhesion molecule-1
and E-selectin by endothelial cells.
The range of mechanisms that are involved in the patho-
genesis of SLE is therefore so diverse that a single
cytokine may exert important effects at a number of differ-
ent levels. TNF-α is the prime example of this phenomenon.
Tumour necrosis factor-α α: the Janus cytokine
In NZB/W F1 mice, the administration of TNF-α reduces
the severity of the lupus-like illness [6]. This observation
has not been repeated in other lupus-prone mouse strains
and the effect of TNF-α in NZB/W F1 mice depends on
the dose and the age of the mice [7].
Rizgar Mageed (University College London, UK)
described a series of experiments designed to clarify the
effect of TNF-α in the NZB/W F1 strain. Immunization of
young NZB/W F1 mice with phosphatidylcholine/ovalbu-
min conjugate leads to the production of anti-double-
stranded (ds)DNA antibodies. This effect is reduced by
administration of recombinant TNF-α and enhanced by
anti-TNFα. Histological examination of lymphoid tissues of
these mice showed that TNF-α reduces the size of T cell
areas, whereas anti-TNF-α promotes T cell function but
disrupts B cell migration.
This work led to the hypothesis that different results would
be obtained in neonatal mice. It was postulated that, in
these mice, anti-TNF-α would enhance T cell function in
such a way as to promote tolerance and reduce autoimmu-
nity. However, the results of the experiment did not support
the hypothesis. Neonatal mice treated with anti-TNF-α
developed increased numbers of T cells, more anti-dsDNA
and antinucleosome antibodies, and increased proteinuria
in comparison with mice treated with a control antibody.
The concept that TNF-α protects against the development
of SLE was also supported by studies conducted in TNF-α-
deficient mice, described by Rachel Ettinger (National Insti-
tutes of Health, Bethesda, MA, USA). These mice develop
antinuclear and anti-DNA antibodies after 15 weeks of age,
but do not develop lupus-like illness. However, the actual
mechanism of this effect is uncertain because mice that lack
both the TNF-55 and TNF-75 receptors do not develop
these autoantibodies. Moreover, the effect is highly depen-
dent on genetic background. TNF–/– mice on a B6 back-
ground do not develop autoantibodies, whereas those on a
mixed B6×B129 background do. Therefore, it appears that
a gene on the 129 background is required to predispose
the TNF-deficient mice to autoimmunity. The development of
autoantibodies is dependent on T cells and on IL-6,162
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because autoantibodies do not develop in TNF-α–/– mice
that lack either T cells or IL-6.
These experiments in murine models suggest that admin-
istration of anti-TNF-α might predispose to the develop-
ment of SLE in humans. Because anti-TNF-α drugs are
now in widespread use in the treatment of rheumatoid
arthritis and Crohn’s disease, there are clinical data relat-
ing to this issue. These data were reviewed by Sir Ravin-
der Maini.
Anti-dsDNA antibodies occur very rarely in patients with
rheumatoid arthritis who have not received anti-TNF-α
therapy but were reported in 7% (11/156) of patients who
had received such treatment [8]. After a single infusion of
infliximab, anti-dsDNA antibodies first develop after a
mean of 6.3 weeks and disappear 4–6 weeks later. When
repeated infusions are given, the anti-dsDNA antibodies
may not disappear until after the last infusion. Anti-dsDNA
antibodies have been reported after treatment with either
infliximab or etanercept, and the dose of anti-TNF-α given
does not affect the likelihood of an anti-DNA response.
The majority of these patients develop IgM but not IgG
anti-dsDNA antibodies and do not develop clinical fea-
tures of SLE. However, clinical SLE can occur following
anti-TNF-α treatment, and there are a number of well doc-
umented cases [9]. The disease is mild, remits when the
drug is stopped, and neither cerebral nor renal involve-
ment has been reported.
Why is the prevalence of clinical SLE after anti-TNF-α treat-
ment so low (0.04–0.2%) when the prevalence of anti-
dsDNA antibody production following such treatment is
much higher (16%)? Similarly, why do TNF-α knockout
mice develop autoantibodies but not a lupus-like illness?
One possibility is that TNF-α exerts two opposing effects.
The first effect operates at the level of T lymphocytes to sup-
press autoantibody formation. The second effect operates
at the level of the target tissues to promote inflammation.
For example, TNF-α is known to activate endothelium, which
could lead to transmigration of leucocytes into the tissues.
The concept that TNF-α could have two opposing effects
in SLE was aptly summarized by Josef Smolen (University
of Vienna, Austria) who dubbed it the Janus cytokine in
honour of Janus, the double-faced god of Roman mythol-
ogy. He pointed out that levels of TNF-α are raised in the
serum of patients with SLE [10] (although levels of the
soluble inhibitor TNF receptor are also raised) and that it
has been detected in renal biopsies of patients with lupus
nephritis. These findings suggest that TNF-α blockade
might be useful as a treatment for SLE.
Smolen reported his experience with four patients with
SLE who had been treated with 5mg/kg infliximab and
concomitant azathioprine. In this open trial, all four patients
showed signs of clinical improvement, even though levels
of anti-dsDNA rose in two cases.
At this point, therefore, the place of TNF-α blockade in the
treatment of SLE is unclear. Although there is a large body
of evidence pointing to protective effects of TNF-α against
the development of autoimmunity in both humans and
mice, there is also evidence that anti-TNF-α could be used
as an agent to reduce tissue damage in patients with SLE.
Interleukin-10
In contrast to TNF-α, there is more consensus concerning
the role played by IL-10 in SLE. IL-10 levels are consis-
tently high in the serum of patients with this condition, and
anti-IL-10 antibodies ameliorate disease in murine models
of SLE. In a small clinical trial, 21 daily doses of intra-
venous monoclonal murine anti-IL-10 antibody led to a
clinical improvement in patients with SLE. This was main-
tained for up to 6 months [11].
Bernard Lauwerys (Universite Catholique de Louvain,
Brussels, Belgium) examined the possible mechanism of
action of IL-10 in SLE. It seems likely that the balance
between IL-10 and IL-12 is important [12]. Supernatants
of cultured peripheral blood mononuclear cells derived
from patients with SLE inhibit allogeneic T cell reactions
in vitro, but this effect can be reversed by adding IL-12 or
anti-IL-10. Levels of the biologically active form of IL-12
(p-70) are low in the serum of patients with SLE, and the
addition of IL-12 inhibits antibody production by SLE
peripheral blood mononuclear cells in vitro.
What is the source of the raised levels of IL-10 in patients
with SLE? B cells are a major source of this cytokine in
patients with certain autoimmune conditions, such as SLE,
Sjögren’s syndrome and rheumatoid arthritis. Dominique
Emilie (Institut Paris-Sud sur les Cytokines, Clamart, France)
described a possible role played by B1a cells in NZB/W F1
mice. These cells are expanded in this strain under
paracrine stimulation by SDF1 secreted from peritoneal
mesothelial cells and autocrine stimulation by IL-10 pro-
duced by the B1a cells themselves. Treatment of NZB/W
F1 mice with either anti-SDF1 or anti-IL-10 reduces protein-
uria and prolongs survival. This is associated with a contrac-
tion of the B1a cell population in the peritoneum.
Consideration of the role played by IL-10 thus raises three
possible avenues for treatment of SLE: anti-IL-10, anti-
SDF1 and IL-12. Only the first of these has been the
subject of a trial in humans (as described above and by
Llorente and co-workers [11]).
Therapy directed against B lymphocytes
A number of lines of evidence implicate B cells in the patho-
genesis of SLE, as sources of antibody, cytokines or as163
antigen-presenting cells. It is therefore logical to conclude
that treatments that target B cells might be useful in SLE.
Michael Ehrenstein described encouraging results
obtained with the monoclonal anti-CD20 antibody ritux-
imab in eight patients with SLE [13]. These patients
showed improvements in disease activity, measured using
the British Isles Lupus Assessment Group index. Improve-
ments in fatigue, arthralgia/arthritis and serositis were
especially striking. Because CD20 is present on all B cells
from the pre-B-cell stage, rituximab therapy leads to pro-
found B cell depletion, but not all of these patients experi-
enced a fall in anti-dsDNA antibody levels and there were
no severe infections. This may be due to the fact that
plasma cells do not carry CD20.
Jane Gross described the use of a soluble inhibitor of
BLyS function (TACI-Ig), which comprises the TACI
receptor fused to an immunoglobulin Fc region. TACI is
one of the three cellular receptors for BLyS. Administra-
tion of TACI-Ig to mice reduces the numbers of mature
B cells and inhibits both T-cell-dependent and -indepen-
dent B lymphocyte responses. Administration of TACI-Ig
to NZB/W F1 mice, either for a short period (between the
ages of 22 and 28 weeks) or chronically, reduced B cell
numbers, anti-DNA antibody levels and proteinuria, and
prolonged survival.
Discussion – where do we go from here?
Peter Lipsky (National Institutes of Health, Bethesda, MA,
USA) noted that the position outlined in the day’s presen-
tations was similar to that pertaining to cytokines in
rheumatoid arthritis 10–15 years ago. There was a certain
amount of experimental evidence suggesting that some
cytokines were involved in pathogenesis of the disease,
and the challenge was to translate that knowledge into the
development of new forms of treatment. It was possible to
discern a hierarchy of importance for cytokines in rheuma-
toid arthritis, which eventually led to the development of
drugs to target the most important cytokines in the hierar-
chy, notably TNF-α and IL-1.
Although no such hierarchy is immediately apparent in
SLE, we have sufficient evidence to consider certain
cytokines as targets in the treatment of this disease. The
most notable examples discussed at the meeting were
TNF-α, IL-10, IL-12 and BLyS.
Is it likely that government agencies or pharmaceutical
companies will fund the large trials necessary to investi-
gate the efficacy of these forms of treatment in SLE?
Peter Lipsky stressed the need to develop reliable bio-
markers of cytokine function before embarking on such
trials, so that we can be sure that any clinical effect of a
drug is actually due to its postulated effect on a particular
cytokine pathway. David Isenberg pointed out that vali-
dated measures of disease activity and damage in SLE
already exist, and could be used to assess the response of
patients to cytokine-modulating agents.
Josef Smolen addressed the difficulty of organizing large
randomized controlled trials of cytokine modulating thera-
pies, especially in a disease such as SLE, which is not
common, and in which even those individuals who are
affected often do not have sufficiently severe disease to
warrant entry into such trials. Perhaps other trial designs
might be considered.
Conclusion
The meeting showed the breadth of interest in the role
played by different cytokines in SLE. A large amount of
work in mice, and a smaller body of evidence on the effects
of anticytokine antibodies in humans, suggests possible
targets for therapy. A major challenge for the future is to
define which of these targets will actually be useful in the
management of SLE. In the light of the success in rheuma-
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